320 related articles for article (PubMed ID: 19727839)
1. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis.
Baskin E; Ozen S; Cakar N; Bayrakci US; Demirkaya E; Bakkaloglu A
Pediatr Nephrol; 2010 Jan; 25(1):111-7. PubMed ID: 19727839
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive treatment for proliferative lupus nephritis.
Tunnicliffe DJ; Palmer SC; Henderson L; Masson P; Craig JC; Tong A; Singh-Grewal D; Flanc RS; Roberts MA; Webster AC; Strippoli GF
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD002922. PubMed ID: 29957821
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
Contreras G; Tozman E; Nahar N; Metz D
Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
[TBL] [Abstract][Full Text] [Related]
5. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.
Lee YH; Woo JH; Choi SJ; Ji JD; Song GG
Lupus; 2010 May; 19(6):703-10. PubMed ID: 20064907
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.
Mejía-Vilet JM; Arreola-Guerra JM; Córdova-Sánchez BM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566
[TBL] [Abstract][Full Text] [Related]
8. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
9. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
[TBL] [Abstract][Full Text] [Related]
10. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.
Houssiau FA; D'Cruz D; Sangle S; Remy P; Vasconcelos C; Petrovic R; Fiehn C; de Ramon Garrido E; Gilboe IM; Tektonidou M; Blockmans D; Ravelingien I; le Guern V; Depresseux G; Guillevin L; Cervera R;
Ann Rheum Dis; 2010 Dec; 69(12):2083-9. PubMed ID: 20833738
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.
Sahin GM; Sahin S; Kiziltas S; Masatlioglu S; Oguz F; Ergin H
Ren Fail; 2008; 30(9):865-9. PubMed ID: 18925525
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis : A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Z Rheumatol; 2017 Dec; 76(10):904-912. PubMed ID: 27638015
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil versus azathioprine for maintenance treatment of lupus nephritis.
Kaballo BG; Ahmed AE; Nur MM; Khalid IO; Abu-Aisha H
Saudi J Kidney Dis Transpl; 2016; 27(4):717-25. PubMed ID: 27424688
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study.
Laskari K; Mavragani CP; Tzioufas AG; Moutsopoulos HM
Arthritis Res Ther; 2010; 12(6):R208. PubMed ID: 21059275
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis.
Basu B; Roy B; Babu BG
Pediatr Nephrol; 2017 Jun; 32(6):1013-1021. PubMed ID: 28191596
[TBL] [Abstract][Full Text] [Related]
16. Sequential therapies for proliferative lupus nephritis.
Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
[TBL] [Abstract][Full Text] [Related]
17. Treatment for lupus nephritis.
Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen.
Fujinaga S; Ohtomo Y; Hara S; Umino D; Someya T; Shimizu T; Kaneko K
Pediatr Nephrol; 2008 Oct; 23(10):1877-82. PubMed ID: 18414900
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis.
Tian SY; Feldman BM; Beyene J; Brown PE; Uleryk EM; Silverman ED
J Rheumatol; 2014 Oct; 41(10):1998-2007. PubMed ID: 25225281
[TBL] [Abstract][Full Text] [Related]
20. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.
Cooper JC; Rouster-Stevens K; Wright TB; Hsu JJ; Klein-Gitelman MS; Ardoin SP; Schanberg LE; Brunner HI; Eberhard BA; Wagner-Weiner L; Mehta J; Haines K; McCurdy DK; Phillips TA; Huang Z; von Scheven E;
Pediatr Rheumatol Online J; 2018 Oct; 16(1):65. PubMed ID: 30348175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
